Osteoarthritis (OA) is a joint disorder caused by the wear and tear of repetitive motion; as a result, the joint’s protective cartilage gradually wears down. The lifetime risk of developing OA in the knee with symptoms including pain, aching, and stiffness, is 40% in men and 47% in women. It is estimated that approximately 19% of Americans aged 45 and older are affected by Knee OA. Knee OA accounts for 83% of the total OA (all types) global burden. Pain and stiffness in the knees, a large weight-bearing joint, often leads to disability which interferes with day-to-day quality of life and demands expensive medical intervention. Due to the limitations of current OA treatment methods, there is an increasing demand for effective and safe alternatives, such as natural health products with pain-relieving potential.

The investigational product, JointAlive^®, is a supplement designed to alleviate knee OA symptoms and to improve knee functionality. The present study will investigate the safety and efficacy of JointAlive^® in reducing knee OA symptoms and improving joint functionality in an otherwise healthy adult population with mild to moderate knee OA. JointAlive^® is a proprietary blend of Epimedium Brevicornum Maxim leaves, Dioscorea Nipponica Makino rhizome, Salvia Miltoiorrhiza Bunge Root and rhizome. To further verify the efficacy of JointAlive® and to build on the results of the previous research, Chenland has begun a new clinical trial on the safety and efficacy of JointAlive® on knee-joint function in adults with knee arthritis. This study is being performed in collaboration with KGK Science Inc.

Study Design

Study Type: Interventional (Clinical Trial)

Estimated Enrollment: 72 participants

Official Title: A Randomized, Double-blind, Placebo-controlled, Parallel Study to Investigate the Safety and Efficacy of JointAlive^® on Improving Knee Joint Function in Adults with Mild to Moderate Knee Osteoarthritis

Eligibility Criteria

Ages Eligible for Study: 40 Years to 70 Years (Adult, Older Adult)

Sexes Eligible for Study: All

Primary Outcome Measures

-Change in knee joint function: Pain (Time Fame: 12 weeks)

This will be determined by change in pain of the identified knee joint from baseline to 12-week post-supplementation between JointAlive^® and placebo, assessed by Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) pain and stiffness scores.

-Change in knee joint function: Stiffness (Time Fame: 12 weeks)

This will be determined by change in stiffness of the identified knee joint from baseline to 12-week post-supplementation between JointAlive^® and placebo, as assessed by Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) pain and stiffness scores.

To learn more about the study, please click here:

https://www.clinicaltrials.gov/ct2/results?cond=&term=JointAlive&cntry=&state=&city=&dist=

The final results of the clinical trial are expected to be published in May, at which time we will share them with our community of partners and consumers.

On March 1^st, 2022, the US Food and Drug Administration (FDA) issued a new qualified structure claim: The FDA approved JointAlive^® as a branded ingredient that helps promote joint comfort, nourish healthy joint cartilage, maintain healthy joints, and improve joint flexibility and mobility (FDA-2022-S-0024-0028).  The structure claim was filed by Chenland in January 2022.  

Expo Breaking News:

Chenland is very excited for our first appearance at the Petfood Forum, where the global pet food industry meets. Find us on the show floor (Booth #2004) in Kansas City, Missouri at the Kansas City Convention Center from May 2^nd to 4^th, to hear about Chenland’s latest research on pet-related natural ingredients which open the door to healthier and safer nutritional support for our four-legged family members.